Overview of parametric survival analysis for health-economic applications
- PMID: 23673905
- DOI: 10.1007/s40273-013-0064-3
Overview of parametric survival analysis for health-economic applications
Abstract
Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric survival analysis methods can be applied to identify an appropriate statistical model for the observed data, which can then be extrapolated to derive a complete time-to-event curve. This paper describes the properties of the most commonly used statistical distributions as a basis for these models and describes an objective process of identifying the most suitable parametric distribution in a given dataset. The approach can be applied with both individual-patient data as well as with survival probabilities derived from published Kaplan-Meier curves. Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial.
Similar articles
-
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x. J Gastroenterol Hepatol. 2010. PMID: 21039835 Review.
-
Sorafenib for the treatment of advanced hepatocellular carcinoma.Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03. Health Technol Assess. 2010. PMID: 20507799 Review.
-
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.J Gastroenterol Hepatol. 2016 Dec;31(12):1978-1985. doi: 10.1111/jgh.13425. J Gastroenterol Hepatol. 2016. PMID: 27118432
-
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24. J Clin Oncol. 2008. PMID: 19029408 No abstract available.
-
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Cited by
-
Long-Term Survivorship of Cervical Spine Procedures; A Survivorship Meta-Analysis and Meta-Regression.Global Spine J. 2023 Apr;13(3):840-854. doi: 10.1177/21925682221125766. Epub 2022 Sep 7. Global Spine J. 2023. PMID: 36069054 Free PMC article.
-
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.Sci Rep. 2024 Jul 31;14(1):17734. doi: 10.1038/s41598-024-68399-3. Sci Rep. 2024. PMID: 39085374 Free PMC article.
-
The Impact of Alternative Specifications of Uncertainty Relating to Extrapolation in Decision Models.MDM Policy Pract. 2025 May 28;10(1):23814683251340058. doi: 10.1177/23814683251340058. eCollection 2025 Jan-Jun. MDM Policy Pract. 2025. PMID: 40453414 Free PMC article.
-
Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer.Front Immunol. 2025 Jun 25;16:1594786. doi: 10.3389/fimmu.2025.1594786. eCollection 2025. Front Immunol. 2025. PMID: 40636104 Free PMC article.
-
Simulation and matching-based approaches for indirect comparison of treatments.Pharmacoeconomics. 2015 Jun;33(6):537-49. doi: 10.1007/s40273-015-0271-1. Pharmacoeconomics. 2015. PMID: 25795232
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources